WINTON GROUP Ltd Sells 21,364 Shares of DaVita Inc. (NYSE:DVA)

WINTON GROUP Ltd reduced its holdings in DaVita Inc. (NYSE:DVA) by 48.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 22,661 shares of the company’s stock after selling 21,364 shares during the quarter. WINTON GROUP Ltd’s holdings in DaVita were worth $3,389,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. MML Investors Services LLC grew its holdings in DaVita by 1.3% in the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock valued at $869,000 after buying an additional 68 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of DaVita by 8.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock worth $133,000 after acquiring an additional 68 shares during the last quarter. Impact Partnership Wealth LLC grew its stake in shares of DaVita by 3.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock worth $290,000 after acquiring an additional 70 shares during the last quarter. Contravisory Investment Management Inc. increased its position in DaVita by 1.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock worth $910,000 after acquiring an additional 73 shares during the period. Finally, Nilsine Partners LLC boosted its holdings in DaVita by 0.8% in the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company’s stock valued at $1,669,000 after purchasing an additional 92 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. StockNews.com downgraded shares of DaVita from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. Barclays lifted their price objective on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Finally, Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus price target of $166.33.

DaVita Stock Performance

Shares of NYSE:DVA opened at $152.73 on Friday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The business’s fifty day moving average price is $157.71 and its two-hundred day moving average price is $157.50. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The stock has a market capitalization of $12.22 billion, a price-to-earnings ratio of 14.22, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.